Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 101 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00528619Phase 1
• A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding PhaseCompletedNCT00528281Phase 1
• Study of XL228 Administered Intravenously to Subjects With Advanced MalignanciesTerminatedNCT00526838Phase 1
• Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT00522938Phase 1/2
• A Safety Study of XL019 in Adults With MyelofibrosisTerminatedNCT00522574Phase 1
• Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCTerminatedNCT00522249Phase 1/2
• Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or ErlotinibCompletedNCT00522145Phase 2
• Sunitinib Malate in Treating East African Patients With Kaposi SarcomaWithdrawnNCT00521092Phase 2
• MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)CompletedNCT00518739Phase 1
• Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00517920Phase 2
• Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00517790Phase 2
• Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid TumorsCompletedNCT00516672Phase 1
• Phase I Study of BMS-690514 in Japanese Patients With Solid TumorsCompletedNCT00516451Phase 1
• Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic PhaseCompletedNCT00514969Phase 2
• Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)CompletedNCT00514488Phase 3
• Study of Intermittent OSI-906 DosingCompletedNCT00514306Phase 1
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT00514228Phase 2
• Study of Continuous OSI-906 DosingCompletedNCT00514007Phase 1
• Phase 1 Study of OSI-930 in Cancer PatientsCompletedNCT00513851Phase 1
• A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of LapatinibWithdrawnNCT00513253Phase 1
• Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerCompletedNCT00513058Phase 1
• Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00511849Phase 1
• Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid LeukemiaCompletedNCT00511303Phase 2
• Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)TerminatedNCT00511121Phase 2
• PTK787 in Refractory or Relapsed Diffuse Large Cell LymphomaTerminatedNCT00511043Phase 2
• Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT00510926Phase 2
• Thyroid Cancer and SunitinibCompletedNCT00510640Phase 2
• Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
• A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical CancerCompletedNCT00510250Phase 1/2
• Phase 1 Study With Sorafenib and SirolimusCompletedNCT00509613Phase 1
• Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00509431Phase 1
• PTC299 and Hormonal Agent for Treatment of Metastatic Breast CancerCompletedNCT00508586Phase 1
• Phase I Irinotecan, 5-Fluorouracil and Leucovorin CombinationCompletedNCT00507091Phase 1
• ZD6474(Vandetanib) + Alimta Combo StudyCompletedNCT00506051Phase 1
• Phase I Chinese PKCompletedNCT00503711Phase 1
• A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in JapanCompletedNCT00503477Phase 1
• Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic TumorsCompletedNCT00503412Phase 1
• Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourCompletedNCT00503204Phase 1
• A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid TumorsCompletedNCT00502567Phase 1
• Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AMLCompletedNCT00502385Phase 1
• Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate CancerCompletedNCT00502164Phase 1
• Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced CancerCompletedNCT00502060Phase 1
• Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver MetastasesCompletedNCT00501605Phase 1
• FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal CancerCompletedNCT00501410Phase 1
• Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GISTCompletedNCT00500188Phase 2
• A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)TerminatedNCT00500006Phase 1
• Phase I FOLFOX CombinationCompletedNCT00499850Phase 1
• Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult SubjectsCompletedNCT00499538Phase 1
• Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast CancerStatus unknownNCT00499525Phase 2
• Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant MelanomaCompletedNCT00498836Phase 2
• Study Comparing 2 New Formulations of HKI-272 in Healthy Adult SubjectsCompletedNCT00498745Phase 1
• Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based ChemotherapyStatus unknownNCT00497250Phase 1
• Phase II Trial of Erlotinib in Advanced Pancreatic CancerCompletedNCT00497224Phase 2
• ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast CancerCompletedNCT00496665Phase 1
• Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal CancerCompletedNCT00496509Phase 1
• MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)CompletedNCT00496353Phase 1/2
• Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCCCompletedNCT00496301Phase 2
• Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLCCompletedNCT00496275Phase 1
• A Phase I/II Study of Sunitinib and DacarbazineTerminatedNCT00496223Phase 1/2
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerActive, not recruitingNCT00494182Phase 2
• A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.CompletedNCT00493155Phase 1
• An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
• Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaStatus unknownNCT00492505Phase 2
• Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
• Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast CancerStatus unknownNCT00491816Phase 2
• Safety Study of XL999 in Adults With Non-Small-Cell Lung CancerTerminatedNCT00491699Phase 1
• Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00490685Phase 2
• A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerStatus unknownNCT00486668Phase 3
• Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With SunitinibCompletedNCT00486538Phase 2
• Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic CancerStatus unknownNCT00486460Phase 3
• Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00483366Phase 1
• A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic MelanomaCompletedNCT00483301Phase 2
• Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00482755Phase 2
• Nilotinib as First-line Treatment of Ph+ CML in Early Chronic PhaseCompletedNCT00481052Phase 2
• A Study of Neoadjuvant Sutent for Patients With Renal Cell CarcinomaTerminatedNCT00480935Phase 2
• A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic CancerCompletedNCT00480584Phase 1
• Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney RemovalCompletedNCT00480389Phase 2
• Efficacy and Safety of Imatinib in SclerodermaCompletedNCT00479934Phase 2
• Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOXCompletedNCT00479583Phase 1
• Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034CompletedNCT00478725Phase 1
• Sorafenib With TACE to Treat Hepatocellular CarcinomaCompletedNCT00478374Phase 1
• Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)CompletedNCT00478114Phase 3
• Iressa as Second Line Therapy in Advanced NSCLC-AsiaCompletedNCT00478049Phase 3
• Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
• Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus SorafenibTerminatedNCT00473486Phase 1/2
• Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem GliomaCompletedNCT00472017Phase 1
• Phase II Trial of Tarceva in Patients With Non-Small Cell Lung CancerStatus unknownNCT00466284Phase 2
• Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung CancerCompletedNCT00466232Phase 1
• Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung CancerStatus unknownNCT00466089Phase 2
• Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)CompletedNCT00464919Phase 2
• Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaTerminatedNCT00464113Phase 1
• Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)CompletedNCT00462995Phase 2
• GW572016 In Patients With Advanced Or Metastatic Breast CancerCompletedNCT00462956Phase 1
• Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid TumorsCompletedNCT00462553Phase 1
• MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyTerminatedNCT00460317Phase 3
• Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal CancerTerminatedNCT00459901Phase 2
• Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck CancerCompletedNCT00458978Phase 2
• Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
• Sorafenib in BAC or Never-Smokers With Lung AdenocarcinomaCompletedNCT00456716Phase 2
• First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never SmokerCompletedNCT00455936Phase 3

← Tyrosine Kinase Inhibitors overview